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Abstract: 
Due to the fact that Europe has lost its major place as a global centre for biomedical research 
the  European  Commission  has  created  Innovative  Medicine  Initiative  (IMI)  as  a  new 
European  Technology  Platform  for  developing  the  European  pharmaceutical  research  and 
development. The European Technology Platform is an instrument under development by the 
European  Commission  to  address  major  economic,  technological  or  societal  challenges 
enabled by Research and Development. IMI is one of the 25 Platforms. It addresses the future 
of biomedical research in the EU with the aim to develop safe and more effective medicines 
in Europe. Its main goal is to revitalize the European biopharmaceutical research environment 
and create a world leadership in this area. Its aim is to remove the obstacles that prevent drug 
development  process  identified  by  industry.  The  initiative  was  developed  by  different 
stakeholders in the form of Strategic Research Agenda (SRA). The basic concepts of the SRA 
are: 1) Prediction of safety, 2) Early indication of efficacy, 3) Knowledge Management and 4) 
Education and Training. There were recommendations developed for each of the concept. 
European Commission decided on substantial budget and financing of the initiative. Europe 
will highly benefit from IMI by increased economic value, creating new jobs, education and 
training,  by  creating  healthier  society  and  citizens.  Patients  and  patient  organisations, 
clinicians, health departments, research councils and general public will all benefit from this 
initiative. 
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1. Introduction 
1. 1. Analysis of strength and weaknesses in Europe 
Europe has an outstanding record of success in biomedical research. It has made innumerable 
contributions to every branch of medicine and the related sciences. There is an equal success 
in pharmaceutical R&D as well. Europe was the cradle of the pharmaceutical industry and 
dominated it for decades. Today the scene is very different. A number of countries outspend 
and outperform Europe. 
 
Europe has lost its major place as a global centre for biomedical research. Despite a five-fold 
increase in the pharmaceutical trade surplus over the last five years investment in R&D has 
declined dramatically compared to the US. There are also new competitors emerging in China 
and  India.  Over  the  last  decade  US  has  invested  far  more  in  public  sector  sponsored 
biomedical research. Europe has not yet matched this level of public sector investment. This 
is affecting and will continue to affect the growth and development in Europe to the detriment 
of both patients and society.  
 
Biomedical  research  not only  improves  health,  it  also  contributes  to  the  improvement  of 
quality and quantity of life. Investment in biomedical research does not only lead to better 
health,  it also creates wealth. The pharmaceutical  industry benefits the EU every  year by 
contributing over 25 billion Euros in net balance payments. It has the most successful high-
tech industry Europe has ever had. The pharmaceutical industry is the fifth largest employer 
in the industrial sector, providing 582,500 highly qualified jobs, investing 19,8 billion Euro 
every year in research and developments and producing annually over 40 billion Euro trade 
surplus (McKillop 2004: 1). 
 
At one of the forums organised by the European Union it was announced that Biomedical 
research is impending a revolution. Understandings of the human genome are those unknown 
technological advances that could  lead to huge new developments. There is an  immense 
scale  of  opportunities  for  developing  biomedical  research  in  Europe  at  present:  from 
improving  treatment  for  the  300  million  people  who  suffer  from  atherosclerosis,  to 
confronting the epidemic of obesity, to treating multi-drug resistant infection. 
 
1. 2. Barriers in the way of developing biopharmaceutical research in Europe 
Why is Europe lagging behind in pharmaceutical R&D, why it is giving up its position of 
enormous strength in biomedical R&D? 
 
One factor is underinvestment in pharmaceutical products and healthcare, which is due to a 
fundamental  difference  in  attitude  to  innovation  in  the  US  and  Europe.  Innovation  is 
estimated more in the US than in Europe – the US is starving for it, while Europe has 
become precautious.   
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There are structural problems as well. Europe is full with laws and regulations therefore it 
is not functioning well. Across Europe there is very little facilitation of academic-industrial 
collaboration that was achieved in the US a decade ago.  
 
A set of market distortions in Europe is an obstacle as well. Different European countries 
have  introduced  various  mechanisms  to  control  supply  and  demand  of  pharmaceutical 
products. According to the Treaty of Rome the free movement of goods and services across 
Europe means that if a country sets the lowest price for a product it becomes the major source 
of  that  medicine  across  Europe.  Parallel  trading  causes  lost  of  profit  for  pharmaceutical 
companies, much of which could be reinvested in R&D in Europe.  
 
It is very costly to produce new drugs and introduction of them often goes all awry due to 
failure  of  the  preclinical  studies  and  to  the  inadequate  regulatory  processes.  The  main 
factors resulting in project failure are either lack of efficiency (25%), clinical safety concerns 
(12%) and toxicological findings in pre-clinical evaluation (20%). The greatest need for the 
pharmaceutical industry is to detect the possibility of failure as early as possible (Ismail and 
Landis 2004 cited in SRA 2005: 10).  
 
Improvements  of  predictive  biology  and  incorporation  of  new  concepts  into  an  improved 
regulatory  framework  would  decrease  the  costs  of  drug  development  and  speed  up  the 
delivery of new drugs to patients. 
 
In most European countries there is still a big gap between academia and industry in case 
of  government  sponsored  research  and  development  that  prevents  coordination  and  joint 
efforts of these stakeholders. 
 
2. Innovative Medicine Initiative: its aims and objectives 
Innovative Medicine Initiative (IMI) is a proposal that deals with different issues connected 
with the future of biomedical research in the EU, and addresses ways of achieving exceeding 
development in the production of safe and more effective medicines, that aims to revitalize 
the European biopharmaceutical research (European Commission 2002). 
 
The  initiative  suggests  that  by  pooling  resources  from  all  stakeholders  –  academia, 
industry, small and medium sized enterprises, regulatory authorities, healthcare providers and 
patient authorities – a quicker access to new drugs may be achieved. 
 
The  overall  objective  of  IMI  is  to  remove  barriers  that  prevent  the  efficiency  of  the 
development  of  new  medicines  to  enable  the  European  biopharmaceutical  industry  to 
become world leader where research is the first priority. 
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2. 1. Creation and Development of IMI 
The  European  Commission  is  developing  European  Technology  Platforms  (ETPs)  to 
promote  innovation  in  Europe.  They  are  an  effective  means  of  defining  research  and 
development  priorities  in  a  number  of  important  areas  of  research  where  Europe  has  to 
become  competitive  both  in  the  medium  and  long  term.  By  means  of  ETPs  Europe  will 
achieve a better structuring of activities in one or another area of Research and Development. 
Europe  is  not  capable  at  present  to  transform  knowledge  into  commercial  products  and 
services. European Technology Platforms are  assisting  in  increase of Europe’s  innovative 
capacity.  
 
ETPs are bringing together stakeholders in key economic sectors in order to:  
  Develop a long term vision of the sector,  
  Create a strategy for delivery, and  
  Establish a management structure to ensure maximum impact.  
The Commission has recently initiated some 25 different Platforms in various areas of R&D. 
There are usually three stages of developing ETPs:  
  getting  together  the  stakeholders  (in  this  industry  plays  an  initiating  role,  the  top 
executives of the leading companies are usually producing a vision document, which 
explains the strategic importance and outlines the development objectives) 
  defining  a  Strategic  Research  Agenda  (it  is  the  main  deliverable  of  the  ETP,  it 
prioritises the research and technological development in the medium and long term, it 
is coordinated by an industry advisory Council, the key elements for implementing of  
SRA are also defined at this stage) and  
  implementation of SRA (during this phase the implementation of SRA with support of 
community research programmes). 
On January 2002, the European Commission published its Communication on Life Sciences – 
a  Strategy  for  Europe  (European  commission  2002).  In  this  document  the  areas  of  life 
sciences and biotechnology are regarded as one of the frontier science and technology areas 
that are most promising for the coming decades. Life sciences and biotechnology are able to 
facilitate the development of many technologies – like information and nano-technology – 
and serve the benefits of both public and private sector. European Technology Platform is 
an  instrument  under  development  by  the  European  Commission  to  face  major  economic, 
technological and societal challenges enabled by Research and Development. It is anticipated 
to contribute to achieving the Lisbon objectives, to develop the European Research Area and 
increase investment in R&D towards the 3% of GDP target (European Commission 2002). 
One of the initiatives of the European Technology Platforms  was “ Innovative Medicine for 
Europe”, under which the European Federation of Pharmaceutical Industries and Associations 
(EFPIA)  has  published  in  May  2004  a  vision  paper  for  Creating  biomedical  R&D 
leadership for Europe to benefit patients and society (EFPIA 2004). 
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This document outlines the four basic concepts on which the initiative is built: 
  Prediction of Safety; 
  Early indication of efficacy; 
  Knowledge management; 
  Education and training. 
2.2. A vision for IMI and a Strategic Research Agenda  
It was envisaged that we need a common European vision and a Strategic Research Agenda. 
The vision was formulated that we have to create biomedical R&D leadership for Europe to 
benefit patients and society. As Europe has a decreased investment in R&D, the European 
Commission  is  exploring  ways  to  achieve  the  Lisbon  goals.  The  European  population  is 
aging,  the  pharmaceutical  R&D  costs  are  increasing,  and  there  is  a  pressure  on  prices. 
Applying new technologies to drug discovery requires a development and active participation 
of all stakeholders, such as Research based Pharmaceutical Industry, Physicians/healthcare 
Professionals,  Academia,  Small  and  Medium  Sized  Enterprises,  Regulators,  EU  policy 
makers.  Science  and  Technology  advances  present  significant  opportunities  for  better 
understanding of mechanisms of diseases and drug development. It promotes a more efficient 
drug discovery and development, faster production of better medicines that result in a more 
healthy EU population.  
3. Strategic Research Agenda (SRA) 
The European Federation of Pharmaceutical Industries and Associations’ (EFPIA) Research 
Directors Group with the participation of the European Commission and the involvement and 
contribution of key actors – the European Medicines Agency (EMEA), national regulatory 
agencies,  clinical  and  academic  researchers  from  various  institutions,  SMEs  and  SME 
associations, patient organisations – has developed The Strategic Research Agenda (SRA 
2005). A series of workshops have been held in the first half of 2005 with involvement and 
contribution of all stakeholders for defining the research that needs to be addressed in order to 
achieve  the  overall  objectives.  The  components  of  the  Strategic  Research  Agenda  for 
Innovative Medicines are 1)  identification of the bottlenecks of the R&D, 2) Analysis of 
current  strength  and  weakness  in  Europe,  3)  recommendations  to  address  bottlenecks,  4) 
definition of the necessary research and technical priorities in the medium and long term, 5) 
estimation of resources and timelines and 6) the framework agreed by all the stakeholders to 
establish Public-Private-Partnership. 
3. 1. Recommendations of SRA for IMI 
The four components recommended at the Strategic Research Agenda are the same as in the 
vision paper: 1. Prediction of drug safety, 2. Early indication of efficacy 3. Knowledge 
management  4. Education and training (SRA 2005, EFPIA 2004). 
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  Creating and functioning a European Centre of Drug Safety in order to identify and 
coordinate research in this respect; 
  Establishing a framework to develop biomarkers indicating the human relevance and 
regulatory utility; 
  Developing a partnership with Regulators to find out innovative clinical trial analyses 
in order to assist acceptance of  biomarkers and to promote data sharing and  joint 
consideration of ethical issues. 
 
2. Improving clinical research regarding efficacy and patient recruitment will be addressed 
with the following actions: 
  using biomarkers as a means of improving prediction of efficacy; 
  developing strategies towards the tailor-made medicines; 
  improving patients’ recruitment using biomarkers; 
  improving consultation of patients and clinical groups; 
  increasing the dialogue with regulatory authorities (SRA 2005, EFPIA 2004). 
 
In this the research priorities are:  
Cancer, Brain disorders, Inflammation diseases, Diabetes mellitus. 
 
3. Knowledge management is important from the point of view of handling the enormous 
amount of data related in the process of biopharmaceutical R &D. 
 
The Knowledge Management Group would like to introduce the following recommendations: 
  develop for complex systems knowledge representation models and data exchange 
standards  
  build a core reference database extracted from the literature 
  design standards for databases and build an expert tool to allow the storage of local 
data in a secured environment.  
 
4. The main recommendations for Education and Training are: 
  Establish a European Medicines Research Academy for education and Training 
for professionals involved in biomedical R&D including regulatory officers; 
  Draft  existing  activities  within  E&T  including  identification  of  European 
centres of excellence and develop programmes, implement these plans in the 
critical areas relevant to the biomedical R&D process; 
  Evaluate options to foster mobility between academia and industry. 
 
 
4. Budget/Financing 
Each year for a period of 7 years, 400 million euros has been required to implement these 
recommendations. The detailed breakdown in million Euros for the four pillars is as follows:  
  For Improved Prediction of Safety          –  165.4 Euros,  Kaleidoscope 
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  For Improved prediction of Efficacy       –  247.7 Euros, 
  For Improved Knowledge Management   –  13.1 Euros and 
  For Improved Education and Training      –  8.2 Euros.  
 
The European Commission together with the biopharmaceutical industry contribute equally to 
the funding of these research projects through the creation of a separate legal structure 
(SRA 2005). 
5. IMI in the FP6  
5. 1. FP6 – PredTox Project
1 
In the FP6 there have been significant advances in four areas of technology carried out in 
PredTox  Project.  The  main  purpose  of  this  project  is  to  estimate  the  use  of  these new 
technologies  in  preclinical  safety  testing  and  to  provide  a  functional  database  containing 
integrated  information  from  the  “omics”  technologies  with  that  from  traditional  toxicity 
endpoints for liver and kidney toxins.    
 
These technologies include: 
  In silico tools which aid the detection and prediction of specific toxicities; 
  Toxico  genomics,  that  detect  changes  in  gene  expression  in  cells  in  response  to 
exposure to a toxic compound; 
  Toxico  proteomics,  to  detect  abnormal  patters  of  protein  sin  cells  in  response  to 
exposure to a toxic compound; 
  Metabonomics,  to  detect  changes  in  endogenous  cellular  metabolism  of  a  cell  or 
organism. 
 
Since the „omics” technologies result in the generation of huge volume of data it is necessary 
to carry out parallel research in bioinformatics/knowledge management and IT in order to 
identify key changes in the measured experimental parameters.  
5. 2. Implementation of IMI 
The  Strategic  research  Agendas  (SRA)  for  Innovative  Medicines  Initiative  has  been 
implemented  through  collaborative  research  in  FP7  and  also  by  means  of  Joint 
Technological  Initiatives  (JTI).    The  approach  is  through  industry,  which  under  the 
leadership  of  EFPIA  and  with  the  agreement  of  key  stakeholders  (Academia,  Regulatory 
agencies, Patent organisations, Clinical researchers, Ethical experts, etc.) has identified the 
main obstacles that are in the way of development of new drugs.  
 
The key features of JTI are arising from Technology Platforms, a critical mass of research 
and innovative effort to be created depending on scale and technical complexity, establishing 
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public/private partnerships and mobilising public and private sources.  An Executive Agency, 
a Joint Undertaking under the article 171. has been organised for implementing  IMI Joint 
Technology  Initiative  (JTI)  ,  which  is  neither  a  public  nor  a  private  entity.  It  is  a 
non-governmental, non-profit organisation under the authority of the national applicable law. 
IMI JTI will consist of a Board, Executive Office, Scientific Committee, Stakeholders Forum 
and  Member  States  Group.  In  the  operational  phase  the  stakeholder  Forum  overlooks 
performance of the initiative and it provides input into the Scientific Committee. 
The Joint undertaking will be adopted by the Council, acting on the proposal after consulting 
with the European Parliament and the Economic and Social Committee. Funds from EU to the 
IMI Joint Undertaking for research projects has been provided through FP7.  Therefore FP7 
adoption is crucial for IMI and its duration is planned till the end of FP7, i.e. 2013. 
 
For  the  successful  implementation  of  IMI,  the  governance  of  it  must  ensure  a  close 
cooperation between the EC and Industry and key stakeholders. It is also planned to involve 
the best European scientists from both public and private sector to ensure updates of the SRA 
and “quality control” of performed research.   
 
Member States are not asked to directly contribute to IMI JTI budget, however contribution 
at a national level are essential for some activities and “Education and training”.  
 
5. 3. Benefits of IMI 
Europe will benefit from IMI in the long run. There will be an increased economic value 
through establishing small and large enterprises in Europe. More jobs will be created in the 
EU,  more  education  and  training  achieved  in  the  biomedical  area.  By  strengthening  the 
European science base, the brain drain will be decreased and the scientific talent attracted to 
appropriate European countries. There will be an increased collaboration with all relevant 
stakeholders. A more effective healthcare will be created for the sake of healthier society and 
citizens of Europe. The following stakeholders and in the following way will benefit from 
IMI: 
 
Patients  and  patient  organisations  will  have  an  improved  quality  of  life  through  more 
appropriate therapies; they will feel more influence on their own health. 
 
Clinicians may benefit from the creation of a novel treatment mechanism; they may better 
influence the development of more appropriate therapies; 
 
Health Departments will gain from improved integration of the developed new therapies 
into the unmet medical needs; more effective therapies will mean more efficient treatment and 
reduced costs for long term care 
 
Pharmaceutical companies will benefit from the reduced risk and a more productive drug 
production; will get a more cost-effective R&D. 
 Kaleidoscope 
Művelődés-, Tudomány- és Orvostörténeti Folyóirat                                                        Vol. 1.No.1 
Journal of History of Culture, Science and Medicine                                                         ISSN: 2062-2597 
 
 
 
 
 
 
www.kaleidoscopehistory.hu 
Gábor Pörzse 
268 
Treasuries will earn from increased GDP/capita, reduced cost of working days due to lost of 
disease, creation of new jobs;  
 
Academia (researchers) will benefit from better infrastructure, an information source, and a 
framework  within  which  they  can  bid  for  work  and  establish  cooperation;  will  get  more 
funding for the research; 
 
Research Councils and other funding bodies will enjoy a framework within which they will 
gain  an  overview  of  current  research  programmes,  avoid  duplication  and  gain  cross 
disciplinary and cross institutional synergy;  
 
General  public  will  benefit  from  increased  awareness  of  diseases,  their  symptoms  and 
consequences.  
6. Conclusions 
European Governments and the Commission have recognised the importance of biomedical 
research and development and are taking steps for their improvement. Governments are trying 
to increase spending on health and education and including steps of long-term commitment to 
national science plans in this respect. The goals set in the Lisbon Agenda are also a step 
forward in this direction. A constant exchange of opinions between the European Ministers, 
representatives of pharmaceutical industry and other different sectors of healthcare industry 
are partially problem-solving. It has been recognised that Europe is lagging behind USA in 
pharmaceutical investment and healthcare. Together Europe may be able to compete with the 
USA and other competitors. The issue is not about the survival of the biomedical research and 
pharmaceutical industry, but whether it will prosper and be among the leaders. Innovative 
Medicine Initiative will contribute to a new approach to drug discovery and development in 
Europe.  Its potential is to change the biopharmaceutical research and development process by 
a  more  systematic  use  of  biomarkers  and by  using  highly  innovative  technologies.  The 
project contributes to a new approach in evaluating risk and its benefit to patients through 
intensive  discussions  with  the  regulatory  authorities.  This  approach  also  favours 
cross-functional  collaboration  between  pre-clinical  and  clinical  scientists  to  promote 
translational medicine. The key deliverable of his initiative is reduced drug development time 
and production of a more targeted medicine to patients with fewer side-effects. The project 
also aims to change the attitude and the way different stakeholders work together. This 
will result in a better and easier interaction with the Regulatory Authorities. This will also 
lead to establishing a new type of collaboration between industry, academia, clinicians 
and patients and contribute to a real shift in culture in this area.  
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